PLSE - パルス・バイオサイエンシズ （Pulse Biosciences Inc）

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested i

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4. The poster highlights the integration of Pulse Bioscience’s nsPFA System with CardioNXT’s iMAP 3-D mapping

In the last trading session, 0.12 million shares of the Pulse Biosciences Inc. (NASDAQ:PLSE) were traded, and its beta was 1.10. Most recently the company’s share price was $3.88, and it changed around $0.14 or 3.74% from the last close, which brings the market valuation of the company to $139.21M. PLSE currently trades at a … Pulse Biosciences Inc. (NASDAQ: PLSE) Could Soon Experience A Sharp Increase In Its Share Price. Read More »

Pulse Biosciences (PLSE) disclosed in a filing on Tuesday that chief financial officer Sandra Gardiner gave notice of her resignation on November 30.The company said it has began a…

Pulse Biosciences (PLSE) CFO Sandra Gardiner is resigning from the bioelectric medicine company.

Pulse Biosciences (PLSE) disclosed in a filing on Tuesday that chief financial officer Sandra Gardiner gave notice of her resignation on November 30.The company said it has began a…

Pulse Biosciences (PLSE) CFO Sandra Gardiner is resigning from the bioelectric medicine company.

NEW YORK, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Natera, Inc. (NASDAQ: NTRA)

Pulse Biosciences Earnings, Revenue Miss in Q3

Pulse Biosciences, Inc. (NASDAQ:NASDAQ:PLSE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin…

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-

Gainers Qurate Retail, Inc. (NASDAQ: QRTEB ) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB ) gained 48.9% to close at $14.00 XORTX Therapeutics Inc. (NASDAQ: XRTX ) jumped 47.2% to close at $1.81 after the company announced topline results from Part 1 of the 3 part Pharmacokinetics Bridging Study showed a substantial increase in oral bioavailability of two versions of its proprietary oxypurinol formulation. ironSource Ltd. (NYSE: IS ) rose 47.1% to close at $3.28 after the company announced an all-stock merger agreement with Unity Software at an approximate $4.4 billion. TDH Holdings, Inc. (NASDAQ: PETZ ) jumped 42.2% to close at $2.93. TDH Holdings reported in SEC filing that the company withdraws of registration statement. NuCana plc (NASDAQ: NCNA ) gained 41.4% to close at $1.37. The Regional Court of Dusseldorf recently ruled in favor of the company, stating that Gilead infringed NuCana''s composition of matter claims in European Patent 2955190.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company''s 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan. The equity awards were approved and issu

Pulse Biosciences, Inc. has determined not to renew its directors and officers liability insurance policies this year due to disproportionately high premiums quoted by insurance companies. Instead, Robert W. Duggan, chairman of the Company''s board of directors, and the Company have entered into a letter agreement, dated May 31, 2022 pursuant to which Mr….

An investigation on behalf of current long term investors in Pulse Biosciences, Inc. (NASDAQ:PLSE) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 06/03/2022 -- Certain directors of Pulse Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Pulse Biosciences, Inc. (NASDAQ: PLSE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: PLSE stocks follows a lawsuit filed against Pulse Biosciences, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PLSE stocks, concerns whether certain Pulse Biosciences, Inc. directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that, the Defendants failed to disclose to investors that the IDE study evaluating the use of the CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints, that, as a result, there was a substantial risk that the FDA would reject Pulse''s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions, and that, as a result of the foregoing, Defendants'' positive statements about the Company''s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.